Nitric oxide is a physiologic signal essential to penile erection. L-citrulline (L-Cit) is converted into L-arginine (L-Arg), the precursor from which nitric oxide is generated. The level of L-Arg and L-Cit in the field of male sexual function remains relatively underexplored. The aim of the study was to evaluate the level of serum L-Arg and of L-Cit in a group of patients with erectile dysfunction. Diagnosis and severity of erectile dysfunction was based on the IIEF-5 and its etiology was classified as arteriogenic (A-ED), borderline (BL-ED), and non-arteriogenic (NA-ED) with penile echo-color-Doppler in basal condition and after intracaversous injection of prostaglandin E1. Serum L-Arg and L-Cit concentrations were measured by a cation-exchange chromatography system. L-Arg and L-Cit levels of men with A-ED were compared with those of male with BL-ED and NA-ED. Median level of L-Arg and L-Cit in 122 erectile dysfunction patients (41 A-ED, 23 ED-BL, 58 NA-ED) was 82.7 and 35.4 lmol/L, respectively. L-Arg and L-Cit levels in control patients were not significantly different (p = 0.233 and p = 0.561, respectively) than in total erectile dysfunction patients. L-Arg and L-Cit levels in control patients were significantly higher (p < 0.001 and p < 0.018, respectively) than in A-ED patients, but no difference (p > 0.50) was observed in controls and in both BL-ED and NA-ED patients. Patients with severe/complete-erectile dysfunction (IIEF-5 < 10) had L-Arg or L-Cit level significantly lower (À17%, p < 0.03; À13%, p < 0.04) and were more frequent (p < 0.01 and p < 0.04) under the respective median level (82.7 and 35.4 lmol/L) than those with mild-erectile dysfunction . L-Arg and L-Cit levels in A-ED were significantly lower (p < 0.007 and p < 0.001, respectively) than in NA-ED patients. Penile echo-colorDoppler revealed that A-ED (peak systolic velocity ≤ 25 cm/sec) was more frequent in men with L-Arg under 82.7 lmol/L or L-Cit under 35.4 lmol/L and in the same population, the median peak systolic velocity values were lower in L-Arg deficient (29 vs. 35; p < 0.04) and also in L-Cit deficient (31 vs. 33, p > 0.3) but without reaching the statistical significance. Our study shows that a significant proportion of erectile dysfunction patients have low L-Arg or L-Cit level and that this condition is more frequent in patients with arteriogenic etiology. Low levels of these nitric oxide synthase substrates might increase the erectile dysfunction risk by reducing the concentration of nitric oxide.
INTRODUCTION
Erectile dysfunction (ED) is a serious health concern for men that has major quality-of-life implications, particularly among aging men (Feldman et al., 1994; Albersen et al., 2012) . Penile erection is a neurovascular event mediated by nitric oxide (NO) (Ignarri et al., 1987; Burnett et al., 1992) . Upon sexual stimulation, NO, synthesized following neural and endothelial activation, increases the activity of guanylate cyclase. The resulting increased concentration of cyclic guanosine monophosphate (cGMP) produces a reduction in cytosolic calcium, leading to smooth muscle relaxation, increased arterial inflow, and corporal veno-occlusion (Rajfer et al., 1992) . Such neurovascular event is strictly related to the integrity of endothelium of the penis. In conditions of increased oxidative stress (Dozio et al., 2013a; Massaccesi et al., 2014) and atherosclerosis with complicated metabolic status, often characterized by overweight and obesity associated with sexual hormone alteration, the progressive endothelial dysfunction is a common pathogenetic feature (Barassi et al., 2009; Dozio et al., 2012) . The discovery of asymmetric dimethylarginine (ADMA) and demonstration of in vivo and in vitro effects on inhibiting NO synthesis has led to discover its role in a wide range of different clinical conditions which share endothelial dysfunction (Paroni et al., 2012) . Phosphodiesterase type-5 inhibitors (iPDE5) enhance NO activity and are currently the most effective oral drugs for the treatment of male ED. However, there are patients who do not respond well to drugs that inhibit NO degradation, potentially those where endothelial dysfunction is the predominant causal factor. Considering the essential role played by NO in physiology of erection, NO donors and first of all L-arginine (L-Arg) and L-citrulline (L-Cit), are among the most attractive alternative to the use of PDE-5 inhibitors. However, at least to the best of our knowledge, the level of plasma aminoacids, and particularly that of L-Arg and L-Cit, in the blood of ED patients has never been investigated.
Aims
The present work aimed to determine their level in a group of men in good health with arteriogenic, non-arteriogenic, and borderline ED, to assess the differences in the concentrations among the three ED subgroups.
METHODS

Investigation protocol
In our center, patients complaining of ED are currently investigated by careful history-taking and clinical andrological examination; then, a few days later, by a panel of examinations, including blood tests, complete blood picture, glycated hemoglobin, glucose, creatinine, total cholesterol, HDL and LDL cholesterol, transaminases, testosterone, prolactin, 17-b-estradiol and the International Index of Erectile Function (IIEF) questionnaire and echo-color-Doppler of both cavernous arteries were assessed. The IIEF questionnaire is a validated, self-administered tool (Rosen et al., 1991 (Rosen et al., , 1997 ), but we only evaluated the answers to the first five (erectile response dominium, IIEF-5) of the 15 questions. Possible scores for the IIEF-5 range from 5 to 25; scores of 22-25 indicate normal erectile function, whereas scores of 21 or below indicate ED (mild 16-20, moderate 11-15, severe 5-10, complete ≤ 4) (Rosen et al., 1997) . Penile echo-color-Doppler was performed in basal conditions and after an intracavernous injection of 10 lg prostaglandin E1 (PgE1) (Aversa et al., 2005) , and the peak systolic velocity (PSV) and end-diastolic velocity (EDV) were recorded at 5, 10, 15, 20, and 25 min after the injection in the proximal portion of the penis. Patients were classified as 'arteriogenic' (A-ED) when their PSV was <25 cm/sec, 'borderline' (BL-ED) with PSV between 25 and 35 cm/sec, and 'nonarteriogenic' (NA-ED) when their PSV was ≥35 cm/sec, or ≤35 cm/sec but >25 cm/sec with concomitant EDV ≤ 0 cm/sec (Pilz et al., 2011; Ellam et al., 2014) . If a patient appeared stressed, he was given a second injection of the same dose of PgE1 and all measurements were repeated. The erection quality was estimated 20 min after each injection. From 30 to 60 min before the penile echo-color-Doppler, participants were placed in a supine position and blood samples were drawn from a cubital vein into Ethylenediaminetetroacetic acid (EDTA) tubes. Samples were centrifuged at 2000 g for 10 min.
The serum was separated and stored at À80°C until analysis. Between the phlebotomy and the storage at À80°C passed no more than 60 min.
Subjects
One hundred and twenty-two patients affected for at least 10 months by ED (defined as persistent inability to attain and maintain an erection sufficient for a satisfactory sexual activity) were recruited from our andrology outpatients clinic and included in this study. A second group of 30 men non-ED matched for age (median: 48 years, range: 29-58), was also investigated. The exclusion criteria were age <25 years and over 60 years, hypertension (>140/90 mmHg in three consecutive recordings at rest), severe kidney diseases, severe retinopathy, liver failure, coronary heart disease, peripheral or cerebrovascular disease, diabetic or non-diabetic neuropathy, endocrine diseases, pelvic surgery, prostatic diseases, drug or alcohol abuse, testes hypertrophy, significant penile deformity, previous or current treatment of ED, vitamins supplementation, and major psychiatric disorders. The patients of the three ED subgroups declared normal physical activity and not to take statins. For all recruited patients, age, cigarette smoking, alcohol consumption, full medical and sexual history, and current therapy were recorded. A physical examination was also performed to obtain data on weight, blood pressure, peripheral pulses, genitals, and neurologic state. Patients who satisfied the inclusion criteria were asked to complete the International Index of Erectile Function (IIEF-5).
This investigation conforms to the principles outlined in the Declaration of Helsinki. Signed informed written consent was obtained from all subjects before their participation in the study. No ethical committee approval was required because no additional blood was needed for this study and this was explained thoroughly to all patients who gave their written informed consent also for laboratory tests and also because this procedure has been reported to be acceptable (Barassi et al., 2010 Dozio et al., 2013b) .
Assays
HbA1c was measured using a high-performance liquid chromatography method (Bio-Rad, Milano, Italy). Serum glucose, creatinine, total cholesterol, HDL and LDL cholesterol, ALT, AST, testosterone, prolactin, and 17-b-estradiol were analyzed with commercially available kits using ModularEVO (Roche, Monza, Italy).
The concentration of L-Arg and of L-Cit was determined by a Biochrom 30plus Amino Analyzer (Biochrom Ltd., Cambridge, UK), a cation-exchange chromatography system (Mondino et al., 1972) . In brief, aminoacid were purified mixing the plasma samples 1 : 1 v/v with 10% sulfosalicylic acid (Sigma Aldrich Corp., St. Louis, MO, USA) containing the internal standard norleucine 500 lmol/L (Sigma Aldrich Corp.) and adding two volumes of lithium citrate loading buffer pH 2.20 (Mondino et al., 1972) . After strong agitation and cooling at 4°C for 5 min, the mixtures were centrifuged 8 min at 8500 g. Supernatants were filtered by syringe filter PVDF membranes (Carlo Erba Reagenti S.r.l., Rodano, Italy) and 100 lL were the operative injection volumes. Post-column derivatization with ninhydrin allowed the detection of aminoacid at the wavelength of 570 nm. Standard lithium citrate buffers with pH 2.80, 3.00, 3.15, 3.50, and 3.55 and ninhydrin reagents utilized during separation were provided ready to use by Biochrom Ltd. One hundred and twenty-five micromolar aminoacid's standard solution was prepared by mixing physiological basis with acids and neutrals and internal standard solution (Sigma Aldrich Corp.). Data analysis was performed by EZCHROME software (Agilent Technologies, Santa Clara, CA, USA). Areas of the peaks were used to determine aminoacid's concentrations and they were expressed in terms of lmol/L. The limits of detection for L-Arg and L-Cit determination are 0.5 and 0.3 lmol/L, respectively. The stability of the two aminoacids in plasma samples is of 2 days at 4°C and of more than 6 months at À80°C.
Statistical analysis
Data are reported as median and range or absolute number and the relative frequency. For statistical analysis, the KruskalWallis test for the comparison of four groups was used. p < 0.05 were considered statistically significant. All analyses were carried out using the SPSS 13.0 statistical package (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical and biochemical characteristics of patients are reported in Table 1 . In the ED patients of this study (median age: 49, range: 25-56), the median IIEF-5 value was 11 (range: 1-23) and the plasma L-Arg and L-Cit levels (median, range in lmol/L) were 82.7 (range: 12.8-213.6) and 35.4 (range: 16.2-98.8), respectively. The levels of L-Arg and L-Cit in the control group were 88.7 (38.4-126.2) and 36.7 (22.5-49.6) lmol/L, respectively. L-Arg and L-Cit levels in control patients were not significantly different (p = 0.233 and p = 0.561, respectively) than in total ED patients. L-Arg and L-Cit levels in control patients were significantly higher (p < 0.001 and p < 0.018, respectively) than in A-ED patients. No difference (p > 0.50) was observed between the levels of L-Arg and L-Cit in controls and in both BL-ED and NA-ED patients. There was a significant difference (p < 0.03) between L-Arg levels in patients with IIEF-5 16-20 (mild ED) and IIEF-5 ≤ 10 (severe/complete ED) that were 83.5 (range: 46.4-151.4) lmol/L and 68.8 (range: 12.8-141.0) lmol/L, respectively. In the same group of ED patients, the L-Cit levels were 35.3 (range: 25.7-88.0) lmol/L and 30.6 (range: 19.5-71.7) lmol/L (p < 0.04).
Of the 122 men included in the study, 41 patients (34%) were classified as having A-ED, 23 patients (19%) as having BL-ED, and 58 patients (47%) as having NA-ED. In A-ED patients, median age was 50 years (range: 33-56), in BL-ED 47 years (range: 32-55), and in NA-ED 49 years (range: 25-56). The median of IIEF-5 values in A-ED patients (8, range: 1-14) were significantly lower (p < 0.01) than in BL-ED patients (15, range: 6-21 and p < 0.01) than in NA-ED patients (15, range: 2-23), but no difference (p > 0.50) was observed between the levels of IIEF-5 among BL-ED and NA-ED patients.
L-Arg levels in A-ED patients (77.4, range: 12.8-115.9) were significantly lower (p < 0.011) than in BL-ED patients (86.2, range: 62.4-110.8 and p < 0.007) than in NA-ED patients (87.7, range: 38.3-213.6 ), but no difference (p = 0.53) was observed between the levels of L-Arg among BL-ED and NA-ED patients (Fig. 1) .
L-Cit levels in A-ED patients (32.4, range: 17.4-46.8) were significantly lower (p < 0.043) than in BL-ED patients (37.5, range: 25.9-50.4 and p < 0.001) than in NA-ED patients (38.3, range:
16.2-98.8), but no difference (p = 0.58) was observed between the levels of L-Cit among BL-ED and NA-ED patients (Fig. 2) . Furthermore, 60.9% (n = 25) and 46.3% (n = 19) of A-ED, 39.1% (n = 9) and 34.7% (n = 8) of BL-ED, 39.6% (n = 23) and 34.4% (n = 20) of NA-ED, have levels of L-Arg < 82.7 and levels of L-Cit < 35.4 lmol/L, respectively. No statistically significant differences (p > 0.05) were found in the three groups regarding the other laboratory parameters evaluated (i.e. HbA1c, glucose, creatinine, ALT, AST, total cholesterol, HDL and LDL cholesterol, testosterone, prolactin, and 17-b-estradiol).
On categorizing patients into groups (Table 2) , those with L-Arg and those with L-Cit levels under and upper the median values (82.7 and 35.4, respectively), there was no significant difference between the four groups in terms of clinical and metabolic parameters. Patients with severe/complete ED (IIEF-5 ≤ 10) were more frequent in the group with L-Arg ≤ 82.7 as compared with those in the group with levels >82.7 (27 vs. 12%) (p < 0.01). The same for L-Cit: patients with severe/complete ED were more frequent in the group with L-Cit ≤ 35.4 as compared with those in the group with levels >35.4 (21 vs. 14%) (p < 0.04). (Paroni et al., 2012) investigated ADMA and symmetric dimethylarginine concentrations in ED patients and showed no different levels of L-Arg in A-ED and NA-ED. Our data do not contradict such results because the A-ED patients of that study had a much less severe dysfunction compared to that of the patients of this study, as reported by the respective IIEF-5 score (11 vs. 8) and PSV (20 vs. 16).
Both L-Arg and L-Cit under their median value had significantly higher frequency in A-ED than in NA-ED patients: 60.9 and 46.3% vs. 39.6 and 34.4%, respectively. The ED patients with L-Arg < 82.7 lmol/L (the median value in the ED group) showed more severe dysfunction (IIEF-5 = 10) in comparison with those with L-Arg > 82.7 lmol/L (IIEF-5 = 12) and to the first group belonged more patients with IIEF-5 < 10: 27 and 12%, respectively. Also, the ED patients with L-Cit lower than the mean value in the ED group (35.4 lmol/L) showed more severe dysfunction (IIEF-5 = 11) in comparison with those with L-Cit > 35.4 lmol/L (IIEF-5 = 14) and to the first group belonged more patients with IIEF-5 < 10: 27 and 12%, respectively. Most importantly, both groups with lower level of L-Arg and L-Cit were characterized by lower PSV (29 vs. 35 and 31 vs. 33, respectively) and a more prevalence of A-ED (27 vs. 12% and 21 vs. 14%, respectively) in comparison with groups with higher level, indicating lower vascular endothelial-dependent vasodilatation in the groups with lower levels of L-Arg or L-Cit.
Clearly, the above results show that an association between L-Arg and L-Cit levels and A-ED exists and this could be because of the low levels of the substrates that produce NO. NO, produced by three different isoform of NO synthases, is one of the most important molecules involved in the physiology of erection. All NO synthases utilize L-Arg as a substrate for NO synthesis (Musicki & Burnett, 2006; Lacchini & Tanus-Santos, 2014) . The NO donor L-Arg is a semiessential aminoacid present in dietary proteins and produced in the body from L-Citr, another semiessential aminoacid synthesized in the intestinal tract from glutamine (Ligthart-Melis et al., 2008) . NO synthase isoforms convert L-Arg to NO, which activates the cGMP pathway, and L-Cit, which can be reconverted by the kidneys into L-Arg to restart a NO-producing cycle (Wu & Morris, 1998) . However, L-Arg is a substrate also used by arginases (Arginase 1 and Arginase 2), expressed in the corpus covernosum (Cox et al., 1999; Bivalacqua et al., 2001; Cama et al., 2003) , and co-localized with NO synthase in the endothelium (Prieto et al., 2011) , which consume L-Arg producing L-ornithine and urea (Durante et al., 2007; Pernow & Jung, 2013) : the higher the arginase activity, the lower the L-Arg level and the NO production will be. Interestingly, Lacchini et al. (2015) recently found that Arginase 2 concentrations are increased in plasma of vasculogenic ED patients and that Arginase 2 levels are positively associated with ED risk. In fact, animal and human studies have demonstrated that NO production in the penis decreases in arteriogenic ED such as that caused by atherosclerosis, trauma, and diabetes (Hink et al., 2001; Grein & Schubert, 2002; Xie et al., 2005) , and furthermore, the supplementation of L-Arg may be effective and well-tolerated therapy in patients with ED (Neuzillet et al., 2013) . It is likely that the increase in Arginase 2 levels actually reflects a more general endothelial dysfunction and may not be specifically related to endothelial dysfunction occurring only in the corpus cavernosum. Nevertheless, this is consistent with the idea that ED would be an early manifestation of a more generic endothelial dysfunction, which over the years would end up presenting itself as coronary disease, or other cardiovascular diseases (Banfi et al., 2008; Inman et al., 2009; Barassi et al., 2012 Barassi et al., , 2015 .
L-Cit, is converted to L-Arg by mammalian cells, including endothelial cells (Hecker et al., 1990; Shuttleworth et al., 1995; Xie et al., 2000; Solomonson et al., 2003; Goodwin et al., 2004) . This recycling pathway might be important in sustaining the production of NO in endothelial cells, especially when L-Arg becomes limiting, as is possible in atherosclerosis. Recently, Morita et al. (2014) showed that a combination of oral L-Cit and L-Arg effectively and rapidly augments plasma NO bioavailability and cGMP concentrations. Moreover, L-Cit supplementation improved erectile function in rats with acute A-ED (Shiota et al., 2013) and, what is more, was able to improve erection in patients with mild ED (Cormio et al., 2011) .
In conclusion, in this study, we demonstrated a higher presence of lower level of L-Arg or L-Cit in A-ED patients compared with NA-ED patients and a lower level of L-Arg or L-Cit in more severe erectile dysfunction patients. Our study shows that, at least in our experimental conditions, the levels of L-Arg or L-Cit, also if significantly lower in A-ED are not sufficiently different to accurately discern between A-ED and NA-ED patients. Then, the low levels of L-Arg or L-Cit may be independent, potentially modifiable erectile dysfunction risk factors, particularly for dysfunction of arteriogenic etiology. It is probable that in conjunction with other risk factors, even where no clinical symptoms were present, the low levels of L-Arg or L-Cit are involved in the mechanism that promotes endothelial dysfunction causing erectile dysfunction.
